-
Mashup Score: 1Belimumab shows promise in neuropsychiatric lupus: Another challenge to find the offender - 2 year(s) ago
Belimumab shows promise in neuropsychiatric lupus. Posterior reversible encephalopathy syndrome (PRES) frequently occurs during active systemic lupus erythematosus (SLE). The nephrotic state is a uni…
Source: onlinelibrary.wiley.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Belimumab treatment of adult idiopathic inflammatory myopathy - 2 year(s) ago
AbstractObjective. To evaluate belimumab addition to standard of care (SoC) in patents with refractory Idiopathic Inflammatory Myopathy (IIM).Methods. We conduc
Source: OUP AcademicCategories: Latest Headlines, RheumatologyTweet-
New #ClinicalTrial results evaluating #belimumab in adult idiopathic inflammatory #myopathy found: ✅ More improvement vs placebo but ❌ No sig diff ❌ No association of B cell changes with clinical response #NCT02347891 #IIM Read more 👇 https://t.co/eN4RtlSFIB
-
-
Mashup Score: 1Biomarker reduction indicates treatment response to Belimumab - 2 year(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation betwee
Source: SoundCloudCategories: Latest Headlines, RheumatologyTweet-
#Lupus #Science & #Medicine and @LupusOrg Dr. Anna Wolska interviews Dr. Andrea Fava from @JohnHopkinsUni1 about #Belimumab treatment in lupus #nephritis. #SLE #Rheumatology #EULAR2023 #LupusNephritis #Treatment #Biomarker #precisionmedicine #trials https://t.co/w4ZzAavQ8F
-
-
Mashup Score: 1Biomarker reduction indicates treatment response to Belimumab - 2 year(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation betwee
Source: SoundCloudCategories: Latest Headlines, RheumatologyTweet-
#Lupus #Science & #Medicine and @LupusOrg Dr. Anna Wolska interviews Dr. Andrea Fava from @JohnHopkinsUni1 about #Belimumab treatment in lupus #nephritis. #SLE #Rheumatology #EULAR2023 #LupusNephritis #Treatment #Biomarker #precisionmedicine #trials https://t.co/w4ZzAavQ8F
-
-
Mashup Score: 1Biomarker reduction indicates treatment response to Belimumab - 2 year(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation betwee
Source: SoundCloudCategories: Latest Headlines, RheumatologyTweet-
#Lupus #Science & #Medicine and @LupusOrg Dr. Anna Wolska interviews Dr. Andrea Fava from @JohnHopkinsUni1 about #Belimumab treatment in lupus #nephritis. #SLE #Rheumatology #EULAR2023 #LupusNephritis #Treatment #Biomarker #precisionmedicine #trials https://t.co/w4ZzAavQ8F
-
-
Mashup Score: 0Belimumab effective for cutaneous lupus erythematosus, regardless of SLE, after 20 weeks - 3 year(s) ago
PHILADELPHIA — Belimumab demonstrated a strong clinical response and significantly reduced flare risk for patients with cutaneous lupus erythematosus, with or without systemic lupus erythematosus, after 20 weeks, said a presenter here.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#ACR22: #Belimumab demonstrated a strong clinical response and significantly reduced flare risk for patients with cutaneous #lupus erythematosus, with or without systemic lupus erythematosus, after 20 weeks #RheumTwitter #MedTwitter https://t.co/7PvyISQfGr
-
-
Mashup Score: 2
PHILADELPHIA — Patients with non-renal systemic lupus erythematosus who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#ACR22: Patients with non-renal systemic #lupus erythematosus who receive #belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants #RheumTwitter #MedTwitter https://t.co/EnWy4T6oTF
-
-
Mashup Score: 1
A systematic review and meta-analysis presented at ACR Convergence 22 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
A systematic review and meta-analysis presented at #ACR22 provide insight into the effects of #belimumab in patient populations with cutaneous #lupus erythematosus, with or without systemic lupus erythematosus. https://t.co/HItvycIqo8
-
-
Mashup Score: 0
Objective Urine proteomic approaches have shown promise in identifying biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by measurement of proteinuria alone. We investigated how the urine proteome changes with treatment response and with belimumab therapy. Methods Urine samples from 54 Belimumab International Systemic Lupus Erythematosus–Lupus…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
1st study to examine the effect of #belimumab, on the #urine proteome in LN: data shows #shifts in profiles are seen with belimumab therapy, with results suggesting that future studies modulation of CD23-mediated immune enhancement pathways in LN response. https://t.co/mMUeiPiRjN
-
-
Mashup Score: 6
Objective Describe available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab. Methods Data collected from belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports up to 8 March 2020 were described. Belimumab exposure timing, concomitant medications and potential confounding factors were…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
🆕 #belimumab use during #SLE 🦋 #pregnancy 🤰 Descriptive summary from multiple data sources ▶️ 1.1 – 21.7% #birthdefects (no consistent pattern) ▶️ 4.2-50% #pregnancylosses Need for specifically designed studies https://t.co/8ABU5IHLgG @RogerAbraminoL @drbags71
-
#Belimumab shows promise in neuropsychiatric #lupus. Find out more in this case study published in #Rheumatology & #Autoimmunity: https://t.co/aEgZ9m0UsT #OpenAccess https://t.co/RLCbrp4Ooi